Table 2.
Clinical characteristics according to serum B2MG levels
| Variable | Low-B2MG group (n=31) | High-B2MG group (n=50) | p-value |
|---|---|---|---|
| Age (yr) | 38.5 (28.5–47.5) | 53.0 (30.0–64.0) | 0.014 |
| Male sex | 20 (64.5) | 37 (74.0) | 0.510 |
| Bulky disease | 2 (6.5) | 5 (10.0) | 0.844 |
| Risk group | 0.002 | ||
| Low | 12 (38.7) | 4 (8.0) | |
| High | 19 (61.3) | 46 (92.0) | |
| LDH > UNL | 14 (45.2) | 41 (82.0) | 0.001 |
| ECOG PS ≥ 2 | 1 (3.2) | 15 (30.0) | 0.008 |
| Stage III/IV | 16 (51.6) | 46 (92.0) | < 0.001 |
Values are presented as median (interquartile range) or number (%). B2MG, β2-microglobulin; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PS, performance status; UNL, upper normal limit.